CAAP Company: ScarX Achieves Full Enrollment in Human Scar Reduction Trial

ScarX Therapeutics, an OBIO CAAP program alumni, announced today it has completed enrollment for its initial human clinical trial of SCX-001, a first-of-its-kind topical treatment to significantly reduce surgical scarring. ScarX expects study results to become available in late 2017.

SCX-001 is applied topically after surgical wound closure to reduce the amount of scar tissue that develops during the healing process. More than 100 million people in the developed world are affected by surgical scarring every year. In the United States, there are an estimated 7.4 million cosmetic and reconstructive plastic surgery procedures annually, leading management to estimate a U.S. target market of $2.5 billion.

ScarX Therapeutics is working to transform scar treatment and prevention. Virtually everyone identifies with the need to minimize scarring and current treatment options are exceptionally limited. SCX-001 is a novel agent that promises to help physicians heal wounds and lead to better outcomes for patients.”
— Stephen Whitehead, President and CEO, ScarX Therapeutics

To read their press release, click here.